Company news

Bristol-Myers Squibb Company news in 2025

Bristol-Myers Squibb Company's news releases, calls and decks from 2025, newest first.

View company

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

December 19, 2025

Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

December 18, 2025

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

December 16, 2025

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

December 11, 2025

Bristol Myers Squibb Announces Dividend Increase

December 10, 2025

Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer

December 9, 2025

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

December 9, 2025

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

December 8, 2025

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 4, 2025

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

December 3, 2025

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

December 1, 2025

Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference

November 26, 2025

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

November 24, 2025

Bristol Myers Squibb to Host Hematology-Focused Investor Event

November 24, 2025

Ability Biotherapeutics Expands its Scientific Advisory Board with the Appointment of Dr. John Burke and Dr. Alan Korman

November 19, 2025

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

November 18, 2025

Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers

November 17, 2025

Update on Phase 3 Librexia ACS Trial

November 14, 2025

Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research

November 12, 2025

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

November 6, 2025

Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

November 5, 2025

Dispatch Bio Announces Clinical Supply and Collaboration Agreement with Bristol Myers Squibb in Solid Tumors

November 4, 2025

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025

November 3, 2025

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes

November 3, 2025

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

October 30, 2025

Global Initiative To Demonstrate Operational Excellence in Nigeria for Metastatic Colorectal Cancer Patients

October 29, 2025

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

October 27, 2025

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

October 25, 2025

Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India

October 17, 2025

Bristol Myers Squibb Foundation Announces $1 Million Donation to Patient Advocate Foundation

October 15, 2025

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform

October 14, 2025

Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types

October 13, 2025

Bristol Myers Squibb and National Community Pharmacists Association Pilot Rural Heart Health Care Initiatives

October 10, 2025

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics

October 10, 2025

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection

October 10, 2025

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

October 1, 2025

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

October 1, 2025

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

September 25, 2025

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

September 23, 2025

Bristol Myers Squibb Commits to Veeva Vault CRM

September 22, 2025

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

September 19, 2025

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

September 16, 2025

Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test

September 15, 2025

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

September 8, 2025

SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025

September 2, 2025

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

August 29, 2025

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 29, 2025

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025

August 25, 2025

FESTIVAL ANNOUNCEMENT: 31st One Mind Music Festival (Feat. Train) Presented by Bank of America and Bristol Myers Squibb

August 18, 2025

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

August 12, 2025

Older news releases →

Calls in 2025

Decks in 2025